Designation of Factor XI Concentrate (Human Coagulation Factor XI) as an Orphan Drug - CSL Behring (Australia) Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was established to regulate the quality, efficacy, and safety of therapeutic goods available in the Australian market. This legislation addresses the need to ensure that therapeutic products are appropriately evaluated and approved before being made available to the public, thereby protecting consumer health. The designation of Factor XI Concentrate (human coagulation factor XI) as an orphan drug under this Act aims to encourage the development of treatments for rare diseases by providing specific incentives and regulatory support. This initiative is overseen by the Therapeutic Goods Administration and seeks to address the significant unmet medical needs associated with rare conditions such as congenital factor XI deficiency and acquired factor XI inhibitors.

Scope and Application

The Therapeutic Goods Act 1989 applies to the designation of Factor XI Concentrate (human coagulation factor XI) as an orphan drug, which is a specific category of therapeutic goods used for the treatment and prevention of rare medical conditions. This Act, administered by the Therapeutic Goods Administration within the Commonwealth of Australia, pertains to the regulation and oversight of therapeutic goods. The designation of Factor XI Concentrate as an orphan drug specifically addresses the treatment and prevention of bleeding in patients with congenital factor XI deficiency or acquired factor XI inhibitors, highlighting its application in rare medical conditions. The Act's application extends to entities involved in the manufacture, importation, supply, or sponsorship of therapeutic goods, thereby encompassing pharmaceutical companies such as CSL Behring (Australia) Pty Ltd. This designation under the Act is geographically and jurisdictionally within the Commonwealth of Australia, and it is subject to the Therapeutic Goods Regulations 1990, which may further extend or restrict its application through subordinate instruments. The orphan drug designation is intended to encourage the development of treatments for rare diseases by providing certain incentives and regulatory support.

Key Provisions

The key operative sections of the Therapeutic Goods Act 1989, as applied in this gazette, involve the designation of Factor XI Concentrate (human coagulation factor XI) as an orphan drug under subregulation 16J(2) of the Therapeutic Goods Regulations 1990 (section 16J). This designation is made by Dr Anthony Gill, the Delegate of the Secretary, for the specific purpose of treating and preventing bleeding in patients with congenital factor XI deficiency or acquired factor XI inhibitors. The product, in its powder for injection form, has been earmarked for this therapeutic use, aligning with the legislative intent to address unmet medical needs. The Act imposes several obligations on the parties involved. Firstly, the Therapeutic Goods Administration (TGA) is mandated to ensure that the orphan drug designation aligns with the criteria set out in the Regulations. This includes verifying that the therapeutic product is intended for a rare condition and that it addresses an unmet medical need. Additionally, the sponsor, CSL Behring (Australia) Pty Ltd, must adhere to the requirements set forth in the Therapeutic Goods Act and the Regulations, including providing necessary data and information to support the orphan drug designation. In terms of legal consequences, any breach of the obligations and requirements under the Therapeutic Goods Act 1989 and the Regulations could lead to significant penalties. The Act provides for both civil and criminal penalties for non-compliance. For instance, under section 20 of the Act, a person who contravenes a provision of the Act or the Regulations may be liable to a fine of up to $222,200 for a corporation or $44,440 for an individual. Additionally, under section 21, a person found guilty of an offence against the Act can face imprisonment for up to two years. These penalties underscore the importance of strict adherence to the legislative requirements governing therapeutic goods in Australia.